Navigation Links
DNA Test Predicts Harmful Effects of Cancer Drug
Date:8/28/2007

Study Questions FDA Guidelines for Colon Cancer Drug

CHAPEL HILL, N.C., Aug. 28 /PRNewswire/ -- Not everyone needs a genetic test before taking the cancer drug irinotecan, and the U.S. Food and Drug Administration should modify its prescription guidelines to say so, according to researchers at the University of North Carolina at Chapel Hill.

Irinotecan, also known by its brand name Camptosar, is used mainly as a second-line treatment for colorectal cancer, the third most common form of cancer in the United States. The FDA currently recommends screening patients for a gene that could make them more susceptible to the harmful side effects of the drug, the most worrisome of which is neutropenia, a blood disorder characterized by an abnormally low number of white blood cells, which decreases the body's ability to fight off infections.

In a paper published in the August 28 Journal of the National Cancer Institute, UNC's Dr. (PhD) and colleagues analyzed data from nine previous studies of irinotecan. They found that only patients who received a medium or high dose of the drug had greater risk of neutropenia if they had two copies of a variation of the gene UGT1A1, known as UGT1A1*28. At lower doses, however, the risk was the same regardless of what UGT1A1 gene the patients had.

"Many institutions saw the FDA's recommendation as authorization to test all patients before treating them with irinotecan, even though many clinicians didn't think it was always necessary since low doses of the drug weren't causing problems," said Prof. Howard McLeod, senior author of the study and director of the UNC Institute for Pharmacogenomics and Individualized Therapy.

"Our review showed that at low doses, the drug is well tolerated and can be taken by most people," McLeod said. "Testing only becomes essential when the dosage increases and genetics become a larger factor in determining what side effects patients experience".

Having a genet
'/>"/>

SOURCE University of North Carolina at Chapel Hill
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Study Presented at the ACC Shows Inflammatory Enzyme Lp-PLA2 Predicts Heart Disease Risk in Metabolic Syndrome Patients
2. Inimex Product Candidate is First Immune Defense Regulator to Cure Infections Without Causing Harmful Inflammation
3. Common Preterm Labor Drug Has More Side Effects Than Alternative, Finds Study from Packard Childrens Hospital and Stanford
4. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
5. XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer
6. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
7. New Data Suggests Less Abuse-Related Effects For OROS Methylphenidate
8. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
9. The International Myeloma Foundation Says New Clinical Trial Results Could Improve Survival While Reducing Side Effects For Many Patients
10. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
11. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 Intarcia Therapeutics, Inc. ... for its lead candidate ITCA 650 (continuous subcutaneous delivery ... baseline HbA1c levels at the 50 th Annual ... Diabetes (EASD). Data from the open-label, phase 3 FREEDOM-HBL ... sugar in patients with poorly controlled type 2 diabetes. ...
(Date:9/19/2014)... September 19, 2014 Reductions in ... many years in people with diabetes type 2 ... term benefits for the kidneys." Australian researchers ... type 2 diabetes leads to persistent reductions in kidney ... The global study has found that, five and ...
(Date:9/18/2014)... 18, 2014  Low T Center endorses the ... Hyattsville, Maryland earlier this ... proper patient population for testosterone therapy (TRT), as ... with TRT. Examining recent claims from studies that TRT ... epidemiological studies do not provide convincing evidence that ...
Breaking Medicine Technology:Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2
... DEERFIELD, IL, June 04, 2007,/PRNewswire-FirstCall/ - Cardiome ... US, Inc. ("Astellas") today,announced results from their ... 2. The trial evaluated the efficacy and ... (iv)") for the treatment of patients who ...
... -- ZymoGenetics,Inc. today announced that interim findings were ... in B-cell chronic,lymphocytic leukemia (B-CLL) at the American ... study included intravenous,administration of higher doses than had ... atacicept was well-tolerated and biologically,active at all dose ...
Cached Medicine Technology:Cardiome And Astellas Announce Positive Results From ACT 2 Trial 2Cardiome And Astellas Announce Positive Results From ACT 2 Trial 3Cardiome And Astellas Announce Positive Results From ACT 2 Trial 4Cardiome And Astellas Announce Positive Results From ACT 2 Trial 5Cardiome And Astellas Announce Positive Results From ACT 2 Trial 6ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 2ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 3
(Date:9/20/2014)... (PRWEB) September 20, 2014 The Arizona ... College (MCC) is celebrating National Manufacturing Day by opening ... enhanced machining, processing and additive manufacturing labs will be ... 3, 2014 at MCC’s Southern and Dobson campus (1833 ... in southeast Lot D. , The AzAMI at MCC ...
(Date:9/20/2014)... Nevada (PRWEB) September 20, 2014 ... extremely successful showing at the PAIN Week conference ... Cosmopolitan Hotel and Casino in Las Vegas from ... MarijuanaDoctors.com primarily attended PAIN Week in the hopes ... as a viable and legitimate tool to treat ...
(Date:9/19/2014)... 20, 2014 Consistent premium price ... the Vision Insurance industry in recent years; however, ... of industry margins. From 2009 to 2014, industry ... provide coverage for routine eye exams and other ... contact lens and refractive surgery. According to IBISWorld ...
(Date:9/19/2014)... September 19, 2014 Unbound , an ... families in regions of the Philippines being affected by both ... than 1,060 families evacuated to the nearest public schools while ... heavy rain and gusty winds to portions of the northern ... flooding. Some homes filled with more than 10 feet of ...
(Date:9/19/2014)... York, NY (PRWEB) September 19, 2014 ... PR News at the Platinum PR and Top Places ... Hyatt in New York City. Camino received honorable mentions ... Shoestring Campaign” — for its work elevating Latina voices ... this incredible organization and be a part of its ...
Breaking Medicine News(10 mins):Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2
... (Nasdaq: GTIV ), a leading provider of comprehensive home,health ... conferences hosted by Oppenheimer & Co., Credit Suisse and,Stephens Inc., ... -- 1:20 p.m. to 1:55 p.m. ET, Monday, November ... & Co. 19th Annual Healthcare Conference in New York. ...
... SGP ) said today that it strongly ... Missouri related to reimbursement by,Missouri,s Medicaid program of ... generics subsidiary, was incorrect.,The company said it will ... all applicable laws and regulations governing reimbursement rules ...
... Technologies Corporation (NASDAQ:DVAX) announced today that it plans to report third quarter ... , ... BERKELEY, Calif. (Business Wire EON) October 30, 2008 -- ... the Oppenheimer 19th Annual Healthcare Conference in New York City on November ...
... Breast Cancer Survivors Learn about the Importance of ... SAN DIEGO, Oct. 30 A large number ... part of the "Know Your,L-Dex" awareness campaign activities ... Houston and Dallas., (Photo: http://www.newscom.com/cgi-bin/prnh/20081030/NY43020 ...
... Conference Call Scheduled Wednesday, November 5, 2008 at 11:00 a.m.,ET ... AFAM ), a leading regional provider of home health ... third quarter,2008 ended September 30, 2008 on Wednesday, November 5, ... the results will begin at 11:00 a.m. ET on,November 5, ...
... International,Inc. (Nasdaq: DATA ), a technology and services ... industry, today announced that,it will host a conference call ... 2008 at 4:30 p.m. ET on Thursday, November 6, ... to dial 412-858-4600 a,few minutes before 4:30 p.m. ET. ...
Cached Medicine News:Health News:Gentiva(R) Health Services to Present at November Investment Conferences Hosted by Oppenheimer, Credit Suisse and Stephens 2Health News:Gentiva(R) Health Services to Present at November Investment Conferences Hosted by Oppenheimer, Credit Suisse and Stephens 3Health News:Schering-Plough to Appeal Jury Decision in Missouri Reimbursement Case 2Health News: Dynavax to Report Third Quarter 2008 Financial Results : -- To Present at Oppenheimer's Healthcare Conference -- 2Health News:'Know Your L-Dex(TM)' (Lymphedema Index) Awareness Campaign Attracts Large Numbers of Breast Cancer Survivors at Komen Race for the Cure(R) Events 2Health News:'Know Your L-Dex(TM)' (Lymphedema Index) Awareness Campaign Attracts Large Numbers of Breast Cancer Survivors at Komen Race for the Cure(R) Events 3Health News:Almost Family, Inc. to Report Third Quarter 2008 Financial Results 2Health News:DATATRAK International Management to Host Conference Call on November 6, 2008 to Discuss Third Quarter and Nine Month Operating Results for 2008 2Health News:DATATRAK International Management to Host Conference Call on November 6, 2008 to Discuss Third Quarter and Nine Month Operating Results for 2008 3
Hartman Mosquito forceps, straight, 3.5"....
Straight 20 mm serrated jaws. Ring handle with ratchet lock and dull finish. Overall length 3.9 inches...
Curved 21 mm serrated jaws. Ring handle with ratchet lock and dull finish. Most popular size or model. Overall length 4.7 inches...
Straight 22 mm serrated jaws. Ring handle with ratchet lock and dull finish. Overall length 4.9 inches...
Medicine Products: